stiripentol has been researched along with Lennox-Gastaut Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Peñas, JJ; Gil Nagel-Rein, A; Sánchez-Carpintero, R; Villanueva-Haba, V | 1 |
| Critchley, D; Gidal, B; Morrison, G; Patsalos, PN; Szaflarski, JP; VanLandingham, K | 1 |
2 review(s) available for stiripentol and Lennox-Gastaut Syndrome
| Article | Year |
|---|---|
Cannabidiol for the treatment of Lennox-Gastaut syndrome and Dravet syndrome: experts' recommendations for its use in clinical practice in Spain.
Topics: Anticonvulsants; Cannabidiol; Clobazam; Clonazepam; Diazepam; Dioxolanes; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Epilepsies, Myoclonic; Humans; Lennox Gastaut Syndrome; Phenobarbital; Practice Guidelines as Topic; Pyrrolidinones; Spain; Triazoles; Valproic Acid | 2021 |
Clinical implications of trials investigating drug-drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs.
Topics: Anticonvulsants; Cannabidiol; Clinical Trials as Topic; Clobazam; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dioxolanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Epilepsies, Myoclonic; Fatty Acids, Monounsaturated; Humans; Lennox Gastaut Syndrome; Valproic Acid | 2020 |